本文選題：急性心肌梗死 + 缺血后適應(yīng)��； 參考：《山東醫(yī)藥》2016年22期

【摘要】：目的觀察低分子肝素聯(lián)合阿昔單抗在急性心肌梗死(AMI)PCI缺血后適應(yīng)中的應(yīng)用效果,并觀察其安全性。方法將108例缺血后適應(yīng)AMI患者隨機(jī)分為觀察組和對(duì)照組各54例,對(duì)照組常規(guī)應(yīng)用低分子肝素抗凝治療,觀察組在此基礎(chǔ)上加用阿昔單抗治療。比較兩組血清肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、心臟超聲參數(shù)、心臟不良事件和出血事件發(fā)生率。結(jié)果兩組治療3 d后血清CK及CK-MB均較治療前降低,且觀察組較對(duì)照組降低(P均0.05)。治療3個(gè)月后,兩組左心室舒張期末容積指數(shù)(LVEDVI)、左心室收縮期末容積指數(shù)(LVESVI)及室壁運(yùn)動(dòng)計(jì)分(WMSI)與治療前比較均降低(P均0.05),而左心室射血分?jǐn)?shù)(LVEF)明顯升高(P均0.05);與對(duì)照組比較,觀察組LVESVI、WMSI降低,LVEF升高(P均0.05)。觀察組心臟不良事件發(fā)生率低于對(duì)照組(P0.05)。兩組出血事件發(fā)生率比較差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論阿昔單抗聯(lián)合低分子肝素能夠有效改善缺血后適應(yīng)AMI患者的心臟功能,降低心臟事件的發(fā)生率,且不增加出血風(fēng)險(xiǎn)。
[Abstract]:Objective to observe the efficacy and safety of low molecular weight heparin (LMWH) combined with acicumab in the treatment of acute myocardial infarction (AMI) after PCI. Methods one hundred and eight patients with ischemic adaptation to AMI were randomly divided into two groups: observation group (n = 54) and control group (n = 54). The control group was treated with low-molecular-weight heparin (LMWH) anticoagulant therapy. Serum creatine kinase (CK), creatine kinase isoenzyme (CK-MBN), cardiac ultrasound parameters, adverse cardiac events and the incidence of bleeding events were compared between the two groups. Results after 3 days of treatment, serum CK and CK-MB in both groups were lower than those before treatment, and the levels of serum CK and CK-MB in the observation group were lower than those in the control group (P < 0.05). After 3 months of treatment, the left ventricular end-diastolic volume index (LVEDVI), left ventricular end-systolic volume index (LVESVI) and wall motion score (WMSI) in both groups decreased by 0.05, while left ventricular ejection fraction (LVEFV) increased significantly (P = 0.05), compared with control group, the left ventricular end-diastolic volume index (LVEDVI), left ventricular end-systolic volume index (LVESVI) and wall motion score (WMSI) were significantly higher than those before treatment (P < 0.05). In the observation group, LVESVI WMSI decreased LVEF and increased P 0.05. The incidence of adverse cardiac events in the observation group was lower than that in the control group (P 0.05). There was no significant difference in the incidence of hemorrhage events between the two groups (P 0.05). Conclusion Axiumab combined with low molecular weight heparin (LMWH) can effectively improve the cardiac function and reduce the incidence of cardiac events in patients with AMI after ischemia without increasing the risk of bleeding.
【作者單位】： 黃驊市人民醫(yī)院;
【基金】：河北省滄州市科技局科技支撐計(jì)劃項(xiàng)目(141302084)
【分類號(hào)】：R542.22

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 高閱春;劉群;陳方;Lim Yeanleng;;冠狀動(dòng)脈內(nèi)支架植入術(shù)聯(lián)合應(yīng)用阿昔單抗對(duì)急性冠狀動(dòng)脈綜合征治療的臨床觀察[J];北京醫(yī)學(xué);2006年07期

2 Bertrand O.F;De Larochellière R;Rodés-Cabau J;黃欣;;比較經(jīng)橈動(dòng)脈冠狀動(dòng)脈支架置入術(shù)后當(dāng)日出院并僅快速推注阿昔單抗與夜間留院治療并快速推注及輸注阿昔單抗的隨機(jī)研究[J];世界核心醫(yī)學(xué)期刊文摘(心臟病學(xué)分冊(cè));2007年06期

3 嚴(yán)銘玉;王駿;王鳴和;;阿昔單抗誘發(fā)血小板減少癥及其治療[J];世界臨床藥物;2009年02期

4 汪亞蕓;補(bǔ)救性PTCA術(shù)患者應(yīng)用阿昔單抗6個(gè)月后的療效評(píng)價(jià)[J];國(guó)外醫(yī)學(xué).心血管疾病分冊(cè);2002年04期

5 尹晴;張志剛;馬亞平;李斌飛;;冠狀動(dòng)脈內(nèi)注射阿昔單抗用于經(jīng)皮冠狀動(dòng)脈介入治療的系統(tǒng)評(píng)價(jià)[J];重慶醫(yī)學(xué);2013年33期

6 Ray M. J.;Walters D. L.;Bett J. N. H.;劉健;;血小板-單核細(xì)胞聚集可預(yù)測(cè)經(jīng)皮冠狀動(dòng)脈介入后肌鈣蛋白增高,且可被阿昔單抗抑制[J];世界核心醫(yī)學(xué)期刊文摘(心臟病學(xué)分冊(cè));2005年10期

7 柳琪林;冠脈支架聯(lián)合阿昔單抗改善急性心肌梗死并發(fā)心源性休克的遠(yuǎn)期生存率[J];中國(guó)危重病急救醫(yī)學(xué);2002年04期

8 Gunasekara A.P.;Walters D.L.;Aroney C.N.;徐永城;;行經(jīng)皮冠狀動(dòng)脈介入的患者應(yīng)用阿昔單抗和大劑量替羅非班的比較研究[J];世界核心醫(yī)學(xué)期刊文摘(心臟病學(xué)分冊(cè));2006年09期

9 ;用阿昔單抗不增加接受PCI病人卒中危險(xiǎn)[J];河南醫(yī)學(xué)研究;2001年03期

10 王建國(guó) ,夏玉昌;替尼普酶與依諾肝素或阿昔單抗合用減少急性心肌梗死后缺血并發(fā)癥發(fā)生率[J];國(guó)外醫(yī)學(xué).藥學(xué)分冊(cè);2002年02期

相關(guān)會(huì)議論文 前2條

1 黃敏;楊人強(qiáng);程曉曙;;急性ST段抬高型心肌梗死患者直接PCI術(shù)中冠脈內(nèi)與靜脈內(nèi)注射阿昔單抗比較:一項(xiàng)薈萃分析[A];江西省第六次中西醫(yī)結(jié)合心血管學(xué)術(shù)交流會(huì)論文集[C];2013年

2 耿召華;劉林瓊;;比較冠狀動(dòng)脈內(nèi)與靜脈內(nèi)運(yùn)用阿昔單抗在進(jìn)行PCI的STEMI中的作用:meta分析[A];中華醫(yī)學(xué)會(huì)第十五次全國(guó)心血管病學(xué)大會(huì)論文匯編[C];2013年

相關(guān)重要報(bào)紙文章 前2條

1 阿勝 編譯 阿華;阿昔單抗30天內(nèi)無明顯療效[N];醫(yī)藥經(jīng)濟(jì)報(bào);2004年

2 呂工;讓你心“動(dòng)”有理由[N];醫(yī)藥經(jīng)濟(jì)報(bào);2002年

，

本文編號(hào)：1919654